Maryland Senate Bill SB435

Maryland 2026 Regular Session

• Introduced: 1/30/26
• Refer: 1/30/26
• Report Pass: 4/13/26

Caption

Public Health - Medetomidine and Xylazine Consumer Protection Act

Impact

The legislation introduces significant changes to existing Maryland public health laws by mandating that all sales of medetomidine and xylazine products are accompanied by documentation proving the intended institutional, veterinary, or scientific use. Retailers will be required to maintain detailed records of all transactions, including copies of identification that verifies the purchaser's age and intended use of the products. Civil penalties for non-compliance will also be enacted, with fines escalating for repeat violations. The revenue from these penalties will contribute to the Maryland Substance Abuse Fund, thereby linking enforcement to broader public health initiatives.

Summary

Senate Bill 435, titled the Public Health - Medetomidine and Xylazine Consumer Protection Act, aims to regulate the distribution and sale of two specific products: medetomidine and xylazine. These products, which are primarily used in veterinary and scientific contexts, will now require retailers to verify the purchaser's intent for legitimate use before any sales. Additionally, the bill prohibits the sale of these substances to individuals under the age of 21, thereby establishing an age restriction to safeguard against misuse.

Contention

While the bill addresses important public health concerns related to the use of these substances, it may generate contention among retailers, especially small businesses, who could face increased administrative burdens and compliance costs. Advocates for stricter regulations argue that such measures are necessary to prevent the misuse of these products, which can have serious implications for public health and safety. Critics, however, may raise concerns about the potential for overregulation and the impact on local businesses that use these products legitimately in their operations.